Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 16 | 2025 | 337 | 6.170 |
Why?
|
| Thymus Gland | 8 | 2020 | 196 | 2.370 |
Why?
|
| Autoantigens | 7 | 2025 | 138 | 1.960 |
Why?
|
| Immune Tolerance | 8 | 2025 | 375 | 1.880 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2018 | 156 | 1.550 |
Why?
|
| Autoimmunity | 4 | 2025 | 189 | 1.490 |
Why?
|
| Prostate | 4 | 2016 | 416 | 1.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2021 | 660 | 1.020 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 424 | 0.970 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 1775 | 0.930 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2023 | 481 | 0.920 |
Why?
|
| Cell Differentiation | 7 | 2023 | 1621 | 0.900 |
Why?
|
| Clone Cells | 7 | 2023 | 219 | 0.810 |
Why?
|
| Neoplasms | 5 | 2018 | 3169 | 0.760 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 202 | 0.750 |
Why?
|
| Antigen Presentation | 4 | 2020 | 229 | 0.730 |
Why?
|
| Lymphocyte Activation | 7 | 2021 | 797 | 0.720 |
Why?
|
| Mice | 21 | 2025 | 12269 | 0.700 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2020 | 287 | 0.690 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2017 | 96 | 0.680 |
Why?
|
| Animals | 27 | 2025 | 28155 | 0.640 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 3435 | 0.630 |
Why?
|
| Transcription Factors | 4 | 2016 | 1691 | 0.620 |
Why?
|
| Lymphopoiesis | 1 | 2020 | 47 | 0.600 |
Why?
|
| T-Lymphocytes | 4 | 2015 | 1275 | 0.590 |
Why?
|
| Dendritic Cells | 3 | 2021 | 536 | 0.580 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 127 | 0.580 |
Why?
|
| Clonal Selection, Antigen-Mediated | 4 | 2020 | 8 | 0.550 |
Why?
|
| Forkhead Transcription Factors | 4 | 2025 | 174 | 0.530 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 355 | 0.510 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 2019 | 48 | 0.500 |
Why?
|
| Mice, Transgenic | 7 | 2025 | 1587 | 0.490 |
Why?
|
| Self Tolerance | 1 | 2016 | 26 | 0.470 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 1077 | 0.440 |
Why?
|
| Repressor Proteins | 2 | 2019 | 443 | 0.410 |
Why?
|
| Mice, Knockout | 6 | 2020 | 2121 | 0.340 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 277 | 0.330 |
Why?
|
| Peptides | 3 | 2021 | 656 | 0.300 |
Why?
|
| Male | 20 | 2025 | 44557 | 0.300 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2021 | 171 | 0.290 |
Why?
|
| Clonal Deletion | 2 | 2020 | 23 | 0.280 |
Why?
|
| Antigen-Presenting Cells | 3 | 2020 | 145 | 0.260 |
Why?
|
| Antigens | 2 | 2021 | 224 | 0.240 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 188 | 0.240 |
Why?
|
| Histones | 1 | 2008 | 361 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 1173 | 0.220 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 365 | 0.210 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 554 | 0.210 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 98 | 0.200 |
Why?
|
| Ligands | 3 | 2021 | 476 | 0.200 |
Why?
|
| Lymphocyte Depletion | 2 | 2021 | 101 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 572 | 0.190 |
Why?
|
| Cell Lineage | 2 | 2016 | 321 | 0.190 |
Why?
|
| Cell Line | 3 | 2021 | 2464 | 0.180 |
Why?
|
| Humans | 24 | 2023 | 93515 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 2 | 2017 | 441 | 0.180 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2023 | 149 | 0.180 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 15 | 0.180 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 48 | 0.180 |
Why?
|
| Insulin | 3 | 2017 | 1185 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 72 | 0.170 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 18 | 0.170 |
Why?
|
| Quinolones | 1 | 2021 | 57 | 0.170 |
Why?
|
| Carcinogens | 1 | 2021 | 101 | 0.170 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2012 | 0.170 |
Why?
|
| Feedback, Physiological | 1 | 2021 | 66 | 0.170 |
Why?
|
| Insecta | 1 | 2021 | 55 | 0.170 |
Why?
|
| Cell Movement | 2 | 2016 | 809 | 0.160 |
Why?
|
| Saliva | 1 | 2021 | 124 | 0.160 |
Why?
|
| CD8 Antigens | 2 | 2019 | 82 | 0.160 |
Why?
|
| Glucose Tolerance Test | 3 | 2017 | 232 | 0.160 |
Why?
|
| Tumor Escape | 2 | 2018 | 53 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 215 | 0.150 |
Why?
|
| Female | 15 | 2025 | 48702 | 0.150 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2019 | 38 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2020 | 184 | 0.140 |
Why?
|
| Homeostasis | 1 | 2021 | 460 | 0.140 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 14 | 0.140 |
Why?
|
| Energy Intake | 1 | 1998 | 97 | 0.140 |
Why?
|
| Arginine | 2 | 2017 | 141 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 173 | 0.130 |
Why?
|
| Tight Junctions | 1 | 2019 | 153 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2018 | 63 | 0.130 |
Why?
|
| Epitope Mapping | 1 | 2017 | 18 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2020 | 730 | 0.130 |
Why?
|
| Coronary Disease | 1 | 1998 | 223 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 482 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 53 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2016 | 42 | 0.120 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 8 | 0.120 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 19 | 0.120 |
Why?
|
| Phenotype | 1 | 2023 | 2544 | 0.120 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 42 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2017 | 277 | 0.120 |
Why?
|
| B7-1 Antigen | 1 | 2016 | 75 | 0.120 |
Why?
|
| Biomarkers | 2 | 2020 | 1910 | 0.120 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2015 | 1 | 0.120 |
Why?
|
| B7 Antigens | 1 | 2015 | 5 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1073 | 0.110 |
Why?
|
| Glucagon | 1 | 2014 | 114 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2015 | 352 | 0.100 |
Why?
|
| Major Histocompatibility Complex | 1 | 2014 | 86 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 824 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 617 | 0.100 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 48 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1660 | 0.100 |
Why?
|
| CD4 Antigens | 1 | 2013 | 80 | 0.100 |
Why?
|
| Kinetics | 4 | 2014 | 1492 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 286 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 939 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1229 | 0.090 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 91 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2013 | 183 | 0.090 |
Why?
|
| Haplotypes | 1 | 2013 | 647 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 337 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 1768 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 556 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 347 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2014 | 712 | 0.070 |
Why?
|
| Hybridomas | 1 | 2008 | 61 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2008 | 470 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2008 | 172 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 113 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2012 | 761 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 401 | 0.060 |
Why?
|
| Melanoma | 2 | 1999 | 495 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 867 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1847 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 504 | 0.050 |
Why?
|
| Middle Aged | 7 | 2021 | 27573 | 0.050 |
Why?
|
| HLA-A2 Antigen | 2 | 1999 | 32 | 0.050 |
Why?
|
| Staining and Labeling | 2 | 1999 | 158 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 38 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2021 | 32 | 0.040 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2001 | 9 | 0.040 |
Why?
|
| Membrane Microdomains | 1 | 2021 | 53 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2001 | 25 | 0.040 |
Why?
|
| Half-Life | 1 | 2001 | 93 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2021 | 84 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2002 | 170 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2021 | 244 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 246 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 154 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 296 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 285 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 331 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 325 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2802 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 887 | 0.040 |
Why?
|
| Risk Factors | 3 | 2016 | 5899 | 0.040 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 18 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 43 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 1999 | 37 | 0.040 |
Why?
|
| Diet Surveys | 1 | 1998 | 21 | 0.040 |
Why?
|
| Adult | 6 | 2021 | 27918 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2002 | 896 | 0.030 |
Why?
|
| Allografts | 1 | 2019 | 205 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1999 | 191 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 319 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2017 | 42 | 0.030 |
Why?
|
| Linear Models | 1 | 1998 | 413 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 47 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 476 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 1321 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1101 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 3502 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 1133 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2495 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 985 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 762 | 0.030 |
Why?
|
| Obesity | 3 | 2014 | 1018 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 754 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1741 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 224 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1161 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2017 | 379 | 0.030 |
Why?
|
| Paresthesia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 93 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 71 | 0.030 |
Why?
|
| C-Peptide | 1 | 2014 | 184 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 224 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 321 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 91 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 367 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 181 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 69 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 301 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 457 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 83 | 0.020 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 100 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 811 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 757 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 383 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 1014 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 2 | 1999 | 12 | 0.020 |
Why?
|
| MART-1 Antigen | 2 | 1999 | 21 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2026 | 0.020 |
Why?
|
| Mutation | 1 | 2001 | 4272 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 937 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 372 | 0.020 |
Why?
|
| Aged | 3 | 2014 | 20434 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2715 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1999 | 444 | 0.020 |
Why?
|
| Adolescent | 2 | 1998 | 9606 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 1999 | 537 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 2 | 1980 | 37 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 767 | 0.010 |
Why?
|
| Triglycerides | 2 | 1980 | 231 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 6930 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1999 | 5 | 0.010 |
Why?
|
| Monophenol Monooxygenase | 1 | 1999 | 9 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1999 | 40 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1999 | 50 | 0.010 |
Why?
|
| Body Weight | 1 | 1980 | 449 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1999 | 68 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 37 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1999 | 94 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1979 | 137 | 0.010 |
Why?
|
| Cell Separation | 1 | 1999 | 200 | 0.010 |
Why?
|
| Cell Communication | 1 | 1999 | 216 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 1906 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1028 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 988 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 555 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 701 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 4560 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1999 | 1415 | 0.010 |
Why?
|
| Indians, North American | 2 | 1980 | 48 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 2303 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1980 | 117 | 0.000 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1980 | 67 | 0.000 |
Why?
|
| Mexico | 1 | 1980 | 73 | 0.000 |
Why?
|
| Arizona | 1 | 1979 | 10 | 0.000 |
Why?
|
| Lipoproteins, LDL | 1 | 1979 | 83 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1979 | 91 | 0.000 |
Why?
|
| Cholesterol | 1 | 1980 | 364 | 0.000 |
Why?
|